Regeneron Pharmaceuticals Inc

REGN

NASDAQ. Currency in USD

697.33 +9.07 ( +1.32% )

Real time prices: September 23

Market Cap.
76.01B
Beta (5Y monthly)
0.28
Price/Earnings
11.70
EPS (TTM)
60.35
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
815,878
1y Target Est.
747.96
Day's Range
681.00
-
699.37
52 Week's Range
538.01
-
754.67

Historical Summary

Performance
EPS growth
Share Buybacks

About Regeneron Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.regeneron.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
105.72M
Employees
10715
Address
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Latest news

AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe

AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma...
By Zacks Investment Research - 2 days ago

Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration...
By Zacks Investment Research - 5 days ago

Intellia (NTLA) Reports Positive Results for CRISPR Candidates
Intellia (NTLA) Reports Positive Results for CRISPR Candidates

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat...
By Zacks Investment Research - 5 days ago

2 Biotech Stocks You Can Buy and Hold for the Next Decade
2 Biotech Stocks You Can Buy and Hold for the Next Decade

It's hard to imagine a world in which pharmaceutical spending doesn't increase year in and...
By The Motley Fool - 5 days ago

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study...
By Zacks Investment Research - 1 week ago

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product...
By Zacks Investment Research - 1 week ago

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech...
By Zacks Investment Research - 1 week ago

A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says

Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rating and a...
By Benzinga - 1 week ago